Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Eur J Cancer. Author manuscript; available in PMC 2012 May 1.
Published in final edited form as:
PMCID: PMC3073413

Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803

D Sargent,1 Q Shi,1 G Yothers,2 E Van Cutsem,3 J Cassidy,4 L Saltz,5 N Wolmark,6 B Bot,1 A Grothey,1 M Buyse,7 A de Gramont,8 and Adjuvant Colon Cancer Endpoints (ACCENT) Group9



The ACCENT group previously established disease-free survival (DFS) with 2 or 3 years median follow-up to predict 5 year overall survival (5yr OS) in stage II and III colon cancer. ACCENT further proposed (1) a stronger association between DFS and OS in stage III than II, and (2) 6 or 7 years necessary to demonstrate DFS/OS surrogacy in recent trials. The relationship between endpoints in trials with oral fluoropyrimidines, oxaliplatin, and irinotecan is unknown.


Associations between the treatment effect hazard ratios (HRs) on 2 and 3yr DFS, and 5 and 6yr OS were examined in 6 phase III trials not included in prior analyses from 1997-2002. Individual data for 12,676 patients were analyzed; two trials each tested oxaliplatin, irinotecan, and oral treatment vs 5-FU/LV.


Overall association between 2/3 yr DFS and 5/6 yr OS HRs was modest to poor (simple R2 measures: 0.58 to 0.76, model-based R2: 0.17 to 0.49). In stage III patients, the association increased (model-based R2≥0.79). Observed treatment effects on 2 yr DFS accurately 5/6 yr OS effects overall and in stage III patients.


In recent trials of cytotoxic chemotherapy, 2 or 3yr DFS HRs are highly predictive of 5 and 6yr OS HRs in stage III but not stage II patients. In all patients the DFS/OS association is stronger for 6yr OS, thus at least 6 year follow-up is recommended to assess OS benefit. These data support DFS as the primary endpoint for stage III colon cancer trials testing cytotoxic agents.


Funded by NCI Grant CA-25224 to the Mayo Clinic to support the North Central Cancer Treatment Group.


Colorectal cancer is the third most common cancer in the United States, with approximately 145,000 new cases diagnosed annually. In patients whose disease is detected at a point where surgical cure is possible but risk of recurrence remains high (stage III), randomized clinical trials have demonstrated that adjuvant chemotherapy reduces the likelihood of recurrence and leads to long-term improvements in overall survival [1,2]. Adjuvant therapy for stage II patients remains controversial but such patients have frequently been included in clinical trials with stage III patients.

Based on a pooled analysis of individual patient data from 18 randomized clinical trials testing 5-FU based treatment, the Adjuvant Colon Cancer Endpoints (ACCENT) Group previously established that the endpoint of disease-free survival (DFS), assessed after 3 years median follow-up, is a valid surrogate endpoint for 5-year overall survival (OS) [3]. Subsequent work suggested that DFS with 2 years median follow-up may also be an appropriate endpoint, and that the association between treatment effects on DFS and OS was stronger in patients with stage III than II disease, however both of these findings required further confirmation [4].

In the last 10 years, multiple new agents (irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab) have been demonstrated to extend survival in patients with colorectal cancer following disease recurrence. In the trials used in the initial ACCENT analysis, which were conducted in the pre-combination therapy era, the median time from recurrence to death was 12 months; currently, this median time is approximately 2 years [5], which suggests that follow-up times of greater than 5 years may be required to observe OS benefits from therapy in more recent or future trials [6]. This prediction has proven accurate for the MOSAIC trial which tested the FOLFOX regimen versus 5-FU/LV, where 6 years of follow-up were required to attain statistical significance for the OS endpoint [7].

In the period since the collection of the original 20,898 patient ACCENT database, multiple additional large trials in the adjuvant setting have been completed and now have mature OS data available (Table 1). The goal of this analysis, using the individual patient data from these six trials not used in the original analysis, was to 1) confirm that DFS remained an appropriate endpoint for adjuvant colon cancer trials, 2) validate DFS with 2 years median follow-up as an endpoint with similar predictive properties as 3 yr DFS, 3) to confirm that the association between HRs based on DFS and OS was stronger in stage III than stage II patients, and 4) to assess whether longer follow-up would strengthen the surrogacy between DFS and OS in more recent trials where median survival following recurrence is extended.

Table 1
Trials included


The methods used in this study are a continuation of those previously used by the ACCENT Group [3]. For the present analysis, ACCENT identified and obtained individual patient data from 6 phase III adjuvant colon clinical trials not included in prior ACCENT analyses (Table 1). These trials accrued patients between 1997-2002, involved 12,676 patients, and included 12 distinct treatment arms (six 5-FU/LV control treatment arms, six experimental arms – two combining oxaliplatin with 5-FU/LV, two combining irinotecan with 5-FU/LV, and two using oral fluoropyrimidine regimens). DFS was defined as the time from randomization to the first event of either disease recurrence or death due to any cause. OS was defined as the time from randomization to death due to any cause. Based on inconsistent long-term follow-up between trials (trial follow-up not mandated past 6 years), for all trials except the C-06 and X-ACT trials data were censored at 6 years from randomization; sufficient follow up was available for the C-06 trial to allow censoring at 8 years from randomization, and for the X-ACT trial all data was used for analysis as for that trial follow-up status was uniformly established on all patients at the date of trial completion.

The primary goal of this analysis was to test the association between the treatment effects on DFS assessed after 2 or 3 years median follow-up (2yr DFS and 3yr DFS respectively) and the treatment effects on OS assessed after 5 or 6 years median follow-up (5yr OS and 6yr OS). For all analyses, efforts were made to replicate actual clinical trial conduct, where patients enter over a period of several years, and thus at any given calendar date have differing durations of follow-up. For each analyses conducted at a specific time point (eg, 3 years), the outcome data for each patient were censored at the point in time at which the median trial-level follow-up was 3 years. For example, if a trial accrued evenly over a period of 3 years, then the median follow-up would be 3 years after 1.5 years had elapsed from the close of randomization. At this point, the first patient enrolled would have 4.5 years of follow-up, whereas the last patient enrolled would have 1.5 years of follow-up.

Treatment effects were measured by the hazard ratios within each trial comparing experimental and control arms for each endpoint. Based on findings in the original ACCENT analysis [4], the current analysis was conducted overall patients and separately by stage, using methods previously described [3]. Sub-analyses by risk group within stage, such as for ‘high-risk’ stage II patients, were not possible due to differences in data collection between the 6 included trials. The primary measures used to assess the association between DFS and OS were 1) the correlation of HRs from each of the six within-study comparisons between the DFS and OS endpoints (assessed as the R2 value from a weighted linear regression on within trial HRs from separate Cox proportional hazards models for the two endpoints, referred to as the ‘simple’ association), and 2) the trial level association from a formal surrogacy model, measured by the trial-level surrogacy measure known as the copula R2 [8] (referred to as the model-based association). Both measures range from 0 to 1, with values close to zero indicating poor association whereas a value of 1 indicates perfect association. The formal surrogacy model uses the individual patient data to estimate the relationship between the risk of a DFS and OS event. Predicted HRs (with 95% prediction intervals) for OS were calculated based on the model previously established based on the original 18 ACCENT trials [3], using the observed HRs for DFS within each of the current six trials.


Overall Association

Of the 12,676 patients, 9395 (74%) were stage III and 3250 (26%) were stage II. The median follow-up on living patients (by reverse Kaplan-Meier) was 6 years. The pattern of recurrence in the six trials was consistent with expectations, with 83% of recurrences occurring in the first 3 years (Figure 1, online only). In this set of trials conduced from 1997-2002, the median survival following recurrence was 20 months.

Figure 1
Rate of recurrence and death by time from randomization (online only)

Considering all trials and all patients, the association between DFS assessed at either 2 or 3 year median follow-up and OS with 5 or 6 year median follow-up was moderate (Table 2), with the simple R2 association between hazard ratios values ranging from 0.58 to 0.76 between the DFS and OS endpoints. However, the model-based R2 values indicated poor association, ranging from 0.17 to 0.49. This association between the DFS endpoints was poor for both 5yr OS and 6yr OS.

Table 2
Association between 2 and 3yr DFS with 5 and 6yr OS, for all patients and stage III patients only

Association in stage III patients

Based on the previous work of the ACCENT group which demonstrated the association between DFS and OS endpoints was stronger in stage III than stage II patients, we assessed the association between the endpoints in the six new trials when limited to stage III patients. In the stage III patients, 69% (2327/3392) and 84% (2852/3392) of patient recurrences occurred in the first 2 and 3 years respectively (compared to 57% (259/455) and 77% (351/455) in stage II patients), and median survival following recurrence in patients with stage III disease was 19 months (compared to 29 months in stage II patients).

When restricted to patients with stage III disease, the association between DFS and OS was strong for all time points considered, with the simple R2 association ranging from 0.89 to 0.93, and the model-based R2 association from 0.79 to 0.88 for the various endpoints (Figure 2, Table 2). Specifically, for example, the simple R2 association between 2yr DFS and 5yr OS was 0.91, and the model-based association was 0.86 (95% CI 0.64-1.00). There was no meaningful difference in association in the stage III patients whether DFS was assessed at 2 or 3 years median follow-up, or whether OS was assessed at 5 or 6 years median follow-up.

Figure 2Figure 2Figure 2Figure 2
Hazard ratios for 2 and 3yr DFS vs 5 and 6yr OS, stage III patients

Four of the six trials included patients with stage II disease. When analyses were restricted to stage II patients from these four trials, the association between DFS after either 2 or 3 median years follow-up and OS with either 5 of 6 years follow-up was poor (simple R2 association ≤0.50 for all associations, model-based associations could not be estimated.)

Predictive model validation

Based on data from the 18 trials included in the original ACCENT publication, a trial-level weighted regression model for predicting the within trial OS HR based on the within trial DFS HR was proposed, both overall and for only stage III patients [3,4]. We used this model, with the observed DFS HRs after 2 years median follow-up from the new six trials to predict the OS results at the 5 and 6 year time points in stage III patients (Table 3, Figure 3). The observed trial level hazard ratio for the OS comparison after 6 years median follow-up was within the 95% prediction limits predicted by the model using 2 yr DFS for all six of the trials. Similar results were observed for the model using 2yr DFS to predict 5yr OS as well as for the model using the 3yr DFS time point to predict 5yr OS (data not shown). However the observed trial level HR for 6yr OS was within the 95% prediction limits from model based on the 3yr DFS for only three of the six new trials (data not shown). Within the combined stage II and III cohort, 5 and 6 yr OS results were within the 95% prediction limit based on 2yr DFS for all six new trials. 3yr DFS predicted (within 95% confidence limits) five and four of the six new trials for 5yr OS and 6yr OS respectively.

Figure 3
Model-based predictions and actual hazard ratios, 2yr DFS as a predictor for 6yr OS, stage III only
Table 3
95% Prediction Intervals for Hazard ratios for 5 and 6yr OS based on observed 2yr DFS hazard ratio, Stage III Patients


Based on individual patient pooled analyses of trials conducted from 1977-1999 using 5-FU based treatment, the ACCENT Group previously validated the DFS endpoint, measured at a time point of 3 years median follow-up, as a valid surrogate endpoint for 5yr OS. The use of the DFS endpoint has allowed for the faster completion of clinical trials, which in turn has allowed more rapid regulatory approval of agents and ultimately allowed effective treatments to reach patients more quickly. In subsequent analyses using the original ACCENT dataset, 2yr DFS was observed to have similar predictive ability to 3yr DFS for long term OS, and the association between DFS and OS was found to be stronger in patients with stage III versus stage II disease. The strong association between 2yr DFS and long-term OS can be explained by the fact that most cancer recurrences occur within the first 2 years, particularly in patients with initial stage III disease.

In the time period since the mid 1990’s, multiple active agents have been introduced for the treatment of recurrent colon cancer. In large part due to the efficacy of such agents, the median survival following cancer recurrence has increased from approximately 12 to, in the studies included in this present analysis, 20 months. This increase in median survival following recurrence will likely diminish the association between DFS assessed after a median follow-up of 2 or 3 years and 5yr OS, potentially requiring longer follow-up to detect an OS benefit since patients are living longer after recurrence [6]. In addition, adjuvant therapy for stage III disease is now based on combination therapy including oxaliplatin, and includes the possibility of oral therapy with capecitabine [9]. Whether the association between DFS and OS is maintained in the presence of these newer treatment options in the advanced disease and adjuvant setting remained an open question.

Here, we have obtained and analyzed data from the six major international trials conducted from 1997-2002, which thus have relatively mature OS follow-up, and which were not included in the initial ACCENT analysis. These analyses clearly demonstrate that for trials with exclusively stage III disease patients and cytotoxic therapy, the association between DFS assessed after 2 or 3 years median follow-up and OS remains intact. The results from these trials do not definitively dictate whether 2yr DFS or 3yr DFS should be ‘preferred’, based on the present data either endpoint is an appropriate option. Based on the prediction models, 2yr DFS provided somewhat more accurate predictions for 5 and 6 yr OS. However, as demonstrated by DeGramont et al through simulation [6] and in the MOSAIC trial in practice [7], 6 or 7 years median follow-up for OS may be required to detect a survival benefit, and thus to demonstrate a strong relationship with 3yr DFS.

The present analysis leaves unanswered the question of whether DFS at an early time point will accurately predict later OS results in a trial in stage II colon cancer or a trial which includes a large proportion of stage II patients. The results after 6 years of median follow-up do not support a strong association, however, in simulations, 7 years of follow-up for OS was found to improve the association between the two endpoints [6]. In the current dataset, 38% (175/455) of patients with stage II disease who had recurred remained alive at the censoring time point for the current analysis. Ultimately mostly of these patients will succumb to their recurrence, thus with extended follow-up the association between treatment effects on DFS and OS could improve. However, as when compared to stage III patients, stage II patients have both longer survival following recurrence [10], and have a higher likelihood of death without recurrence [4], in trials of stage II patients alone the association between DFS and OS will likely never be statistically robust. For example in the MOSAIC trial, despite a trend towards improved DFS in stage II patients after 3 years follow-up, absolutely no benefit in OS was observed at the 6 year time point [7]. Unless DFS is considered a clinically relevant endpoint on its own merits, analyses based on data to date support the use of OS as the most appropriate endpoint for trials in unselected stage II disease.

Clinical trials in adjuvant colon cancer now include the possibility of both chemotherapeutic and biologic agents. Such new therapies may only delay, as opposed to prevent, recurrence. This paradigm is strongly suggested by the results of the C-08 trial which tested Bevacizumab in addition to FOLFOX therapy in patients with stage II and III disease. In C-08, there was strongly suggestive evidence of an early reduction in recurrence risk in the first year of therapy, while the Bevacizumab was being delivered, which disappeared once treatment was stopped and thus after three years of follow-up no significant DFS benefit was observed [11]. In a trial where the agent being tested may have such a mechanism of action (delay as opposed to prevent recurrence), the use of short-term endpoints such as DFS must be carefully considered [12]. Uncertainty in the impact of a therapy argues for a longer-term DFS endpoint, such as 3yr or even 4yr DFS as opposed to 2yr DFS. In addition, the endpoint must allow adequate time past the completion of a therapy to assess the delay versus prevention of recurrence hypothesis. While no data is available to provide a firm recommendation, we recommended a DFS endpoint that is assessed at least 2 years after the completion of protocol therapy.

An important limitation of this analysis is that it is based on only 6 trials. Analyses of surrogate endpoints with a limited number of trials are known to suffer from large variability in estimation, which likely was manifest in our analysis of the pooled stage II and III patients where the model-based and simple R2 measures differed greatly [13]. However, given the size and complexity of adjuvant colon cancer trials, these 6 trials are the entire population of large trials conducted world-wide in this time period, and as such provide the best available evidence. The ACCENT group will continue to work with individual trialists to include data from newly maturing adjuvant trials, such as the XELOXA trial [9].

In summary, in this analysis of six trials of 12,676 patients added to the ACCENT database, we have validated that for trials in patients with stage III disease testing cytotoxic therapies, results based on DFS assessed after 2 or 3-yr median follow-up are valid and appropriate primary endpoints. In trials that include a substantial proportion of stage II patients, at the present time data are inadequate to provide confidence that 2 or 3 year median follow-up results will accurately predict OS results at 5 or 6 years. As median survival following recurrence continues to improve, all adjuvant trials should follow patients for at least 8 years to allow a complete assessment of OS, which remains an endpoint of clinical importance despite the fact that in the elderly population, competing causes of death take on a greater role as follow-up duration increases. The strong association observed based on previous and current studies, as well as the lengthy required follow-up and associated confounding for OS in recent trials, supports DFS as the most appropriate endpoint for adjuvant clinical trials in patients with stage III colon cancer treated with both 5 FU based cytotoxic chemotherapy regimens.


Supported by NCI Grant CA25224

This work was funded by a grant from the US National Cancer Institute to the Mayo Clinic to support the North Central Cancer Treatment Group. The funding source played no role beyond providing funding for this project. This project was reviewed and approved by the Mayo Clinic Institutional Review Board.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1) Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358. [PubMed]
2) Sargent DJ, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb. 2027(6):872–877. [PMC free article] [PubMed]
3) Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1;23(34):8664–70. [PubMed]
4) Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A. End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007 Oct. 1025(29):4569–4574. [PubMed]
5) Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey J-N, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug. 127(22):3677–3683. [PMC free article] [PubMed]
6) de Gramont A, Hubbard J, Shi Q, O’Connell MJ, Buyse M, Benedetti J, Bot B, O’Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: Simulations based on the 20,898 patient ACCENT Data Set. J Clin Oncol. 2010 Jan. 2028(3):460–5. [PMC free article] [PubMed]
7) Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 July 1;27(19):3109–3116. [PubMed]
8) Burzykowski T, Molenberghs G, Buyse M, et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. Appl Stat. 2001;50:405–422.
9) Haller D, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll H. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer. (NO16968/XELOXA study) European Journal of Cancer Supplements. 2009 September;7(3):4.
10) O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andre T, Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008 May 10;26(14):2336–41. [PubMed]
11) Wolmark N, Yothers G, O’Connell MJ, Sharif S, Atkins JN, Seay TE, Feherenbacher L, O’Reilly S, Allegra CJ. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27(suppl):18s. abstr LBA4.
12) Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician’s perspective. Stat Methods Med Res. 2008 Oct;17(5):529–35. [PubMed]
13) Renfro LA, Shi Q, Bot B, Sargent D. An assessment of meta-analytic measures for evaluating time-to-event surrogate endpoints in clinical trials; Joint Statistical Meetings; Washington, DC. 2009; abstr. 304742.
14) André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351. [PubMed]
15) Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704. [PubMed]
16) Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059–2064. [PubMed]
17) Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 June 1;25(16):2198–2204. [PubMed]
18) Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol. 2007 Aug. 1025(23):3456–3461. [PubMed]
19) Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, Andre T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009 July 1;27(19):3117–3125. [PubMed]